Castle Biosciences, Inc. CSTL

Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17
P/E ratio	0.00	41.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
P/S ratio	3.28	2.23	2.68	4.33	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
P/FCF ratio	39.74	20.25	0.00	0.00	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡
P/Operating CF	41.87	30.38	31.67	(98.92)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
P/B ratio	2.39	1.62	1.50	1.49	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡
Price to Tangible BV	3.04	2.12	2.15	2.18	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡
EV/Sales	2.44	1.38	1.64	2.54	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/EBITDA	0.00	25.44	0.00	0.00	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡
EV/Operating CF	13.03	7.05	(63.99)	(8.36)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/FCF	29.55	12.51	(18.72)	(7.39)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Quick Ratio	4.99	6.97	5.90	7.81	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Current Ratio	5.26	7.29	6.20	8.09	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Debt/EBITDA	46.20	(15.73)	3.98	3.85	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Debt/Assets	1.79%	1.95%	0.00%	2.98%	‡‡‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡
Debt/Equity	0.02	0.02	0.00	0.03	‡‡‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Asset Turnover	0.62	0.67	0.49	0.30	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating CF/Net income	(2.66)	3.56	0.10	0.62	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capex/Depreciation	(0.98)	(3.04)	(1.99)	(0.59)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡
Depreciation/Fixed assets	0.38	0.18	0.27	0.64	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Interest Coverage	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
ROE	(5.21%)	4.31%	(14.54%)	(16.56%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
ROA	(4.35%)	3.71%	(12.76%)	(14.76%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
ROIC	(14.72%)	3.13%	(28.67%)	(29.60%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡
Cash ROIC	(4.24%)	1.81%	(4.90%)	(8.34%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Return on Tangible Assets	(6.20%)	5.04%	(21.02%)	(24.82%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Accounts Receivable Turnover	7.28	7.42	7.12	6.72	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Accounts Payable Turnover	5.55	7.01	6.00	8.80	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Inventory Turnover	7.73	7.49	7.55	10.67	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Days of Receivables	46.00	56.30	63.61	62.53	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Days of Payables	96.15	41.84	83.32	53.95	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Days of Inventory on Hand	52.69	49.32	64.44	45.38	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Research and Development Expense of Revenue	15.06%	15.67%	24.40%	32.77%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Selling, General and Administrative Expense of Revenue	66.62%	60.24%	81.97%	104.35%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Intangible Assets out of Total Assets	0.17	0.20	0.26	0.28	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡
Share Based Compensation of Revenue	13.33%	15.15%	23.30%	26.50%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡
Graham Net Nets	0.22	0.38	0.40	0.41	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Graham Number	0.00	15.49	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Earnings Yield	(2.16%)	2.44%	(9.84%)	(11.33%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow Yield	2.52%	4.94%	(3.27%)	(7.93%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Revenue per Share	11.88	11.96	8.20	5.26	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating CF per Share	2.22	2.34	(0.21)	(1.60)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capex per Share	(1.24)	(1.02)	(0.51)	(0.21)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡
Free Cash Flow per Share	0.98	1.32	(0.72)	(1.81)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Cash per Share	10.33	10.55	9.07	9.93	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Shareholders Equity per Share	16.24	16.41	14.60	15.32	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Interest Debt per Share	0.00	0.00	0.00	0.00	‡‡‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Book value per Share	16.24	16.41	14.60	15.32	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow	28.37	36.56	(19.23)	(47.09)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Working Capital	292.42	310.76	247.97	256.16	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capital Expenditures	(35.98)	(28.31)	(13.61)	(5.44)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Current Asset Value	253.41	284.75	233.56	244.11	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Receivables	47.30	44.76	30.89	20.38	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Payables	12.81	8.58	7.50	3.64	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Inventory	9.19	8.04	5.96	3.00	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Assets	554.90	492.29	450.33	454.95	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Common Equity	463.35	423.55	395.21	405.45	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/EBIT	0.00	52.76	0.00	0.00	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡
Capex to Sales	0.10	0.09	0.06	0.04	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡
Net Profit Margin	(7.02%)	5.49%	(26.15%)	(48.99%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Price to Operating Income	0.00	85.38	0.00	0.00	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡

Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Subscribe now